405 related articles for article (PubMed ID: 34885716)
1. Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.
Amewu RK; Sakyi PO; Osei-Safo D; Addae-Mensah I
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885716
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Editorial (Thematic Issue Role of Heteroaromatics as Anticancer Agents).
Kaur H
Anticancer Agents Med Chem; 2016; 16(10):1204. PubMed ID: 27592681
[No Abstract] [Full Text] [Related]
4. Naturally Occurring O-Heterocycles as Anticancer Agents.
Avula SK; Das B; Csuk R; Al-Harrasi A
Anticancer Agents Med Chem; 2022; 22(19):3208-3218. PubMed ID: 34749628
[TBL] [Abstract][Full Text] [Related]
5. Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
Bera H; Chigurupati S
Eur J Med Chem; 2016 Nov; 124():992-1003. PubMed ID: 27783978
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Review of N-Heterocycles as Cytotoxic Agents.
Kumar D; Jain SK
Curr Med Chem; 2016; 23(38):4338-4394. PubMed ID: 27516198
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy.
Kumar L; Verma S; Joshi K; Sharma S
Crit Rev Ther Drug Carrier Syst; 2023; 40(3):47-94. PubMed ID: 36749083
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Homsi J; Daud AI
Cancer Control; 2007 Jul; 14(3):285-94. PubMed ID: 17615535
[TBL] [Abstract][Full Text] [Related]
9. Sprouting strategies and dead ends in anti-angiogenic targeting of NETs.
Carrasco P; Zuazo-Gaztelu I; Casanovas O
J Mol Endocrinol; 2017 Jul; 59(1):R77-R91. PubMed ID: 28469004
[TBL] [Abstract][Full Text] [Related]
10. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD
Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144
[TBL] [Abstract][Full Text] [Related]
12. Medicinal Potential of Heterocyclic Compounds from Diverse Natural Sources for the Management of Cancer.
Singh M; Sharma P; Singh PK; Singh TG; Saini B
Mini Rev Med Chem; 2020; 20(11):942-957. PubMed ID: 32048967
[TBL] [Abstract][Full Text] [Related]
13. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
[TBL] [Abstract][Full Text] [Related]
14. Thymidine phosphorylase-mediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo.
Tsukagoshi S; Saga Y; Suzuki N; Fujioka A; Nakagawa F; Fukushima M; Suzuki M
Int J Oncol; 2003 May; 22(5):961-7. PubMed ID: 12684660
[TBL] [Abstract][Full Text] [Related]
15. Natural compounds as angiogenic enzyme thymidine phosphorylase inhibitors: In vitro biochemical inhibition, mechanistic, and in silico modeling studies.
Javaid S; Shaikh M; Fatima N; Choudhary MI
PLoS One; 2019; 14(11):e0225056. PubMed ID: 31743355
[TBL] [Abstract][Full Text] [Related]
16. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
Relf M; LeJeune S; Scott PA; Fox S; Smith K; Leek R; Moghaddam A; Whitehouse R; Bicknell R; Harris AL
Cancer Res; 1997 Mar; 57(5):963-9. PubMed ID: 9041202
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.
Lu H; Klein RS; Schwartz EL
Clin Cancer Res; 2009 Aug; 15(16):5136-44. PubMed ID: 19671868
[TBL] [Abstract][Full Text] [Related]
18. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
Heryanto B; Lipson KE; Rogers PA
Reproduction; 2003 Mar; 125(3):337-46. PubMed ID: 12611597
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
20. Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents.
Azad I; Nasibullah M; Khan T; Hassan F; Akhter Y
J Mol Graph Model; 2018 May; 81():211-228. PubMed ID: 29609141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
